NCT03659357 is a clinical trial in Intestinal Neoplasms, sponsored by Tongji Hospital.

Who is sponsoring NCT03659357?

NCT03659357 is sponsored by Tongji Hospital.

What condition does NCT03659357 study?

NCT03659357 studies Intestinal Neoplasms.

Is NCT03659357 still recruiting?

NCT03659357 is currently status unknown. Last updated 15 October 2019.

Last reviewed 2019-10-15 · How we verify

NCT03659357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Small Bowel Tumor With Dual-phase Enhanced Computed Tomography (CTE) and Magnetic Resonance Enterography (MRE)

Status unknown Last updated 15 October 2019

What this trial tests

trial in Intestinal Neoplasms in 150 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
30 September 2020

30 September 2021

Quick facts

Lead sponsor	Tongji Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 September 2018
Primary completion	30 September 2020
Estimated completion	30 September 2021
Sites	1 location across China

Conditions studied

Intestinal Neoplasms — all drugs for Intestinal Neoplasms →

Sponsor

Tongji Hospital

Who can join

Eligibility, any sex, with Intestinal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: To compare the accuracies of computed tomographic (CT) enterography and magnetic resonance (MR) enterography for the detection and radiomics characterization of small-bowel tumors (including gastrointestinal stromal tumors, adenomas and lymphomas, etc); Hypothesis: MR enterography was noninferior to CT enterography for the diagnosis and evaluation of small bowel tumors in generally well-distended small bowel.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intestinal Neoplasms

Currently open trials in the same condition.

NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT05551052 — CRC Detection Reliable Assessment With Blood · active not recruiting
NCT04949282 — Spanish Series of Patients Treated With the Radionuclide Lutetium177 · recruiting

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03659357 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 15 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03659357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing